Saint Barnabas Medical Center, an RWJBarnabas Health facility, has announced one of the first cloud-based data management platforms in the country to identify, track, follow and monitor patients with pancreatic cysts.
The National Comprehensive Cancer Network has published new best practice recommendations for Management of COVID-19 infection in patients with cancer.
A comprehensive review by University of North Carolina researchers and colleagues of hundreds of publications, incorporating more than two dozen articles on prevention screening for lung cancer with low-dose spiral computed tomography, shows there are both benefits and harms from screening.
JScreen, a national public health initiative based out of Emory University School of Medicine’s Department of Human Genetics, has established a program that offers at-home testing for more than 60 cancer susceptibility genes associated with hereditary risks for breast, ovarian, prostate, colorectal, skin and other cancers.
A John Hopkins study suggests gaining a better understanding of physical frailty could eventually help people age more healthfully.
FDA has approved Fotivda (tivozanib), a kinase inhibitor, for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
FDA has granted accelerated approval to Yescarta (axicabtagene ciloleucel) for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Health Canada has approved Keytruda (pembrolizumab), for the first-line treatment, as monotherapy, for adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.
Surface Oncology and Merck have entered into a clinical trial collaboration to evaluate the safety and efficacy of combining Surface’s SRF388, an investigational antibody therapy targeting IL-27, with Merck’s Keytruda (pembrolizumab), an anti-PD-1 therapy.
Syapse has renewed its strategic collaboration with Pfizer.
